{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T19:09:57Z","timestamp":1760987397760},"reference-count":37,"publisher":"Elsevier BV","issue":"7","content-domain":{"domain":["jprasurg.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Plastic, Reconstructive & Aesthetic Surgery"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.bjps.2013.03.008","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T10:16:35Z","timestamp":1365243395000},"page":"912-916","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of basal cell carcinoma with surgical excision and perilesional interferon-\u03b1"],"prefix":"10.1016","volume":"66","author":[{"given":"R.","family":"Wettstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Erba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Itin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.F.","family":"Kalbermatten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjps.2013.03.008_bib1","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjps.2013.03.008_bib2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Hoff Von","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjps.2013.03.008_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CJI.0b013e318174a4df","article-title":"Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma","volume":"31","author":"Hofmann","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.bjps.2013.03.008_bib4","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1172\/JCI119814","article-title":"Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1\/Fas)-CD95 ligand-induced suicide","volume":"100","author":"Buechner","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bjps.2013.03.008_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1365-2133.2002.05069.x","article-title":"Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion","volume":"147","author":"Sterry","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1524-4725.2009.01163.x","article-title":"Donor site morbidity of the posterior conchal region","volume":"35","author":"Erba","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":"The interferons. Mechanisms of action and clinical applications","volume":"266","author":"Baron","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.bjps.2013.03.008_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaad.2006.02.035","article-title":"Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy","volume":"54","author":"Tucker","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/archderm.1990.01670320053006","article-title":"The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas","volume":"126","author":"Edwards","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/0190-9622(90)70276-N","article-title":"Intralesional interferon therapy for basal cell carcinoma","volume":"23","author":"Cornell","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/014107689108400907","article-title":"Treatment of basal cell carcinoma with intralesional interferon alpha-2b","volume":"84","author":"Healsmith","year":"1991","journal-title":"J R Soc Med"},{"key":"10.1016\/j.bjps.2013.03.008_bib12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2340\/00015555-70512514","article-title":"Intralesional interferon-alpha 2b treatment of basal cell carcinoma","volume":"70","author":"Thestrup-Pedersen","year":"1990","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/j.bjps.2013.03.008_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000246688","article-title":"Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma","volume":"190","author":"Chimenti","year":"1995","journal-title":"Dermatology"},{"key":"10.1016\/j.bjps.2013.03.008_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1346-8138.1996.tb04040.x","article-title":"Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma","volume":"23","author":"Alpsoy","year":"1996","journal-title":"J Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0304-3835(95)03741-E","article-title":"Intralesional alfa-2a interferon therapy for basal cell carcinoma","volume":"91","author":"Do\u011fan","year":"1995","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bjps.2013.03.008_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0190-9622(92)70158-C","article-title":"Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery","volume":"27","author":"Stenquist","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1440-0960.1992.tb00084.x","article-title":"Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review","volume":"33","author":"McDonald","year":"1992","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib18","first-page":"381","article-title":"Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b","volume":"9","author":"Fern\u00e1ndez-Vozmediano","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0190-9622(91)70111-E","article-title":"Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression","volume":"24","author":"Buechner","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0190-9622(86)70192-8","article-title":"Treatment of basal cell carcinoma with intralesional interferon","volume":"15","author":"Greenway","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/1471-2407-9-262","article-title":"Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study","volume":"9","author":"Anasagasti-Angulo","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bjps.2013.03.008_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00044011-200525100-00005","article-title":"Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon alpha-2a: evaluation of long-term follow-up results","volume":"25","author":"Bostanci","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.bjps.2013.03.008_bib23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-4632.2009.03576.x","article-title":"Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFN alpha-2b and topical imiquimod 5% cream","volume":"48","author":"Turan","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0301-4738.37590","article-title":"Surgery of basal cell carcinoma around the lacrimal canaliculus can be necessary after primary treatment with intralesional interferon alpha 2b","volume":"56","author":"Huerva","year":"2008","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.bjps.2013.03.008_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1054\/bjps.2002.3948","article-title":"Incomplete excision of basal cell carcinoma: a prospective multicentre audit","volume":"55","author":"Kumar","year":"2002","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/02844310701694811","article-title":"Incomplete excision of basal cell carcinoma in the subunits of the nose","volume":"42","author":"Wettstein","year":"2008","journal-title":"Scand J Plast Reconstr Surg Hand Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1445-2197.2002.02351.x","article-title":"Incomplete excision of basal cell carcinomas: a retrospective audit","volume":"72","author":"Dieu","year":"2002","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1054\/bjps.2000.3394","article-title":"Incidence of incomplete excision in surgically treated basal cell carcinoma: a retrospective clinical audit","volume":"53","author":"Kumar","year":"2000","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/02844310701282138","article-title":"Morphoeic basal cell carcinoma of the face","volume":"41","author":"Erba","year":"2007","journal-title":"Scand J Plast Reconstr Surg Hand Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib30","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/PRS.0b013e3181ea450d","article-title":"What is the best surgical margin for a basal cell carcinoma: a meta-analysis of the literature","volume":"126","author":"Gulleth","year":"2010","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.sap.0000226930.67941.7f","article-title":"High magnification assessment improves complete resection of facial tumors","volume":"57","author":"Wettstein","year":"2006","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib32","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2133.2007.08040.x","article-title":"Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy","volume":"157","author":"Macbeth","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2013.03.008_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1600-0560.2008.01019.x","article-title":"Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases","volume":"36","author":"Ball","year":"2009","journal-title":"Cutan Pathol"},{"key":"10.1016\/j.bjps.2013.03.008_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1445-2197.1996.tb01184.x","article-title":"Incompletely excised basal cell carcinoma: a management dilemma?","volume":"66","author":"Sussman","year":"1996","journal-title":"Aust N Z J Surg"},{"key":"10.1016\/j.bjps.2013.03.008_bib35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000300116","article-title":"Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up","volume":"220","author":"Wetzig","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.bjps.2013.03.008_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/978-3-642-59410-6_29","article-title":"Intralesional interferon in basal cell carcinoma: how does it work?","volume":"160","author":"Buechner","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.bjps.2013.03.008_bib37","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1084\/jem.20101102","article-title":"Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons","volume":"207","author":"Gregorio","year":"2010","journal-title":"J Exp Med"}],"container-title":["Journal of Plastic, Reconstructive & Aesthetic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1748681513001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1748681513001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T12:12:21Z","timestamp":1715170341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1748681513001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1748681513001265"],"URL":"https:\/\/doi.org\/10.1016\/j.bjps.2013.03.008","relation":{},"ISSN":["1748-6815"],"issn-type":[{"value":"1748-6815","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of basal cell carcinoma with surgical excision and perilesional interferon-\u03b1","name":"articletitle","label":"Article Title"},{"value":"Journal of Plastic, Reconstructive & Aesthetic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjps.2013.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}